Now it is quite difficult to determine the true cause of the development of epilepsy. This is especially true of idiopathic and cryptogenic forms, which develop for no apparent reason. In such a process, there are no changes in the brain, or other condi tions that can trigger the development of pathology. If there is an idiopathic form of epilepsy, the patient is supposed to get a disability. This is due to the fact that this disease leads to a significant limitation of a person in his work activity. We will not expand on how epilepsy is treated in the complex, because with each individual focal diagnosis the doctor prescribes his own set of drugs. But we will only talk about general principles. So, in most cases, the disease can be cured without surgery, only medicamentously. This does not mean, however, the rejection of social and therapeutic assistance, without which it will be dif ficult for a person to adapt in the society.
pilepsy is a chronic disease of the brain, the main manifestation of which are epileptic seizures. Advances in the treatment of epilepsy are achieved by improving the diagnosis of various forms of the disease and individualization of therapy. Focal epilepsy, the clinical core of which is focal seizures, including those with impaired con sciousness and secondary generalization, is the most common form of the disease in adults up to 6070% of cases, about half of which have tempo ral epilepsy [1] . There is a symptomatic focal epilepsy caused by brain damage of a known organ ic nature, and presumably symptomatic (crypto genic). Diagnosis of focal epilepsy includes the fol lowing stages, allowing to verify the diagnosis and assess the patient's health [2] : 1) the study of the seizure seizures; 2) anamnesis collection; 3) study of neurological and somatic status; 4) neuropsychological testing (assessment of the cognitive and emotionalemotional sphere); 5) electroencephalographic studies, including video electroencephalography; 6) neuroimaging (magnetic resonance imaging of the brain, including with the use of regimes that allow to optimize the diagnosis of hippocampal lesions and heterotopia of gray matter); 7) laboratory studies (clinical and biochemical analysis of blood, ultrasound examination of inter nal organs).
Only after confirming the epileptic nature of seizures and diagnosing epilepsy does the doctor determine the tactics of the patient's management. The goal of epilepsy treatment is to save the patient from attacks and improve the quality of life. In patients with rare seizures (less than 1 per year), one can refrain from prescribing antiepileptic drugs (PAD) [3] , explaining to the patient the importance of compliance with sleep and rest, refusal of alco hol. In some cases, when an epileptogenic focal brain lesion is detected (according to the methods of neuroimaging), treatment begins after the first attack. According to international and Russian rec ommendations, treatment for the first time diag nosed epilepsy begins in the monotherapy regime. In Uzbekistan, as the monotherapy of the first line in focal epilepsy, the following PADs were record ed: basic (carbamazepine, valproate), a new gener ation of PAD (lamotrigine, oxcarbazepine, topira mate, levetiracetam, gabapentin). Pregabalin, lacosamide is registered in our country as an addi tional therapy. "The old" PAD (barbiturates, diphe nine) are not drugs of the first order of choice. Antiepileptic drugs of the new generation differ from the basic and "old" drugs with better tolerabil ity [2, 4, 5] . The choice of PET should be based on data on efficacy, tolerability, side effects, pharma cokinetics, pharmacodynamics, mechanisms of action, interdrug interactions, the rate of titration (the speed of reaching the required doses) of the PET, as well as patient data (age, sex, comorbid pathology). As a rule, PAD is prescribed in minimal doses with subsequent increase. Observance of the recommended regimens of titration of doses of drugs is extremely important for achieving good tolerability and, as a consequence, compliancepatient compliance with medical recommendations. In some patients with frequent seizures, especially in hospital settings, it is possible to force the titra tion of the PAD [6] . With insufficient effectiveness or poor tolerance of monotherapy, the first line of the patient is transferred to a second line monother apy. Only in the absence of effect or poor tolerance of 23 drugs in the monotherapy regimen, duother apy is recommended, and later on in certain cases simultaneous administration of three PADs is also acceptable [7] . Drug Interactions. Ineffectiveness of drug the rapy is the reason for the patient's additional exam ination, revision of the diagnosis. The general algo rithm for assigning a PET is shown in different sources [8] . Rational duotherapy helps to increase the effectiveness of treatment and minimize dose related side effects. Choosing duotherapy, the doc tor should remember the mechanisms of action of the PAD, the summation of side effects, the possi bility of interaction of the PAD with each other and with other medicines. Interdrug interactions are most often realized through the induction and inhi bition of hepatic enzymes involved in drug metabo lism. For example, carbamazepine, phenobarbital, phenytoin are powerful inducers of hepatic enzymes, reduce plasma levels in many drugs. Levetiracetam, gabapentin, pregabalin, lacosamide are not metabolized in the liver, do not affect hepat ic enzymes and therefore have an almost perfect pharmacokinetic profile [1, 3, 9] . Consider the prob lem of interdrug interactions on the example of lamotrigine. Lamotrigine is metabolized in the liver by glucuronization with the enzyme glucuronosyl transferase (UGT1A4). The concentration of lamot rigine in the blood plasma increases with the simul taneous administration with valproate a glu curonidation inhibitor [4, 10] , but decreases under the influence of phenytoin, carbamazepine, pheno barbital, primidon inducers of glucuronidation. Thus, the combination of valproate with lamotrig ine allows to reach the effect by using smaller doses than in monotherapy.
Therapeutic drug monitoring. At present, the method for determining the concentration of PAD in biological fluids, in particular in blood plasma and saliva, called therapeutic drug monitoring (TDM), is becoming more accessible. Therapeutic drug monitoring is a reliable method of assessing com pliance and individual pharmacokinetic parameters in patients with epilepsy [11] . The use of TDM allows studying intraindividual changes in differ ent clinical situations, comparing the obtained data with the recommended allowable concentrations (formerly used the term "therapeutic concentra tions") for all PADs. The recommended allowable concentrations have been established on the basis of numerous studies. It is shown that when finding the concentration values within the indicated corridor, the majority of patients note a combination of effi cacy with good tolerability [12] . Indications for car rying out TDM in the application of various PADs are as follows [7] :  establishing an individual therapeutic concen tration when a satisfactory clinical effect is achieved. Knowledge of this parameter will allow further in the event of the possible appearance of endogenous (body mass fluctuations, development of somatic pathology, etc.) and exogenous (the need for taking other medications, etc.) factors to correct treatment;  confirmation of the toxic effects of drugs, which is expected on the basis of identifying the characteristic clinical symptoms;  checking compliance (adherence to treatment), especially with resistant seizures or disruption of drug remission;  control of the concentration of the drug in the blood in clinical cases associated with potential pharmacokinetic variability (in children, the elderly, patients with concomitant diseases, with a change in the dosage form of the drug for example, the use of generics);  monitoring the concentration of the drug in the blood in situations where it is expected to be an obligate change, for example, during pregnancy, with polytherapy;  control of the concentration of drugs with non linear pharmacokinetics (phenytoin). On the basis of a comparison of the characteristics of the phar macokinetics of PAD, the following groups of drugs are distinguished, depending on the degree of necessity of TDM on the background of their administration:
 TDM is necessary carbamazepine, phenobar bital, phenytoin;  TDM is recommended ethosuximide, lamot rigine, oxcarbazepine, valproate;  TDM is useful, especially if there is a further increase in the dose of the drug, topiramate;  TDM is probably useful levetiracetam, gabapentin.
Pregnancy, lactation and labour period with epilepsy. Among patients with epilepsy, special cat egories are identified that require a special approach women of childbearing age and elderly patients [2, 8] . When choosing a PAD for women of child bearing age, the following aspects should be taken into account: the interaction of PAD and oral con traceptives, teratogenicity of PAD, changes in plas ma PAD concentrations during pregnancy, and the ability of PAD to cause postnatal cognitive deficits in children. Since most of the estrogen component of oral contraceptives is hydroxylated by the enzyme CYP3A4, the received PAD inducers of this enzyme reduce the effectiveness of hormonal contraception. If translation into PAD without enzymeinducing properties is not possible, recep tion of contraceptives containing at least 50 μg of the estrogen component or the rejection of hormon al contraception is recommended [6, 7, 11] . The 18% decrease in the concentration of synthetic proges terone under the influence of lamotrigine has no clinical significance. Activation of glucuronidation of lamotrigine under the influence of the proges terone component of oral contraceptives leads to a decrease in its level in blood plasma on the days of taking contraceptives as compared to the level on days without hormones, and such fluctuations can trigger an attack [12] . Teratogenicity of PAD is assessed as data on pregnancy registries of women with epilepsy are accumulated, since controlled studies are impossible for ethical reasons. To date, there are data on the increase in the frequency of large abnormalities of development in 23 times against the background of valproate (dosedepend ent effect). The frequency of developmental abnor malities rises to 10% on the background of poly therapy. The dosedependent effect of lamotrigine on the frequency of developmental abnormalities and, probably, the teratogenic effect of topiramate is determined. Disruption of drug remission during pregnancy can be associated with increased clear ance of PAD, vomiting, weight gain [1, 2] .
Therefore, the increase in the clearance of lam otrigine, phenytoin, oxcarbazepine, levetiracetam during pregnancy is described, which requires cor rection of the doses of the drugs. Measurement of the level of intelligence in children aged 2 years and older, born of mothers who took PAD during preg nancy, made it possible to evaluate PAD for the ability to cause a postnatal cognitive defect [5, 9] . It has been shown that valproate is probably associat ed with a cognitive deficiency, phenytoin and phe nobarbital may be associated with cognitive deficits, and carbamazepine probably does not cause cognitive deficits in children [4, 10] . Undoubtedly, the received data require specifica tion, but the doctor should do everything possible to minimize the risk of negative impact of the PAD. The allocation of elderly epilepsy patients to a spe cial group is due to the following pharmacokinetic features [8, 12] :
 Decreased bioavailability of drugs (mainly due to impairment of absorption);  increasing in the content of the free fraction of the PAD due to the reduction of the fraction asso ciated with the protein;  increasing in the plasma levels of metabo lized drugs due to a decrease in enzyme activity;  increasing in the level of plasma in the blood of the kidneys, due to a decrease in clearance.
Initial doses of PAD in epilepsy patients, as a rule, are therapeutic. The rarity of the development of resistant to therapy seizures in the elderly allows you to lead patients on monotherapy [5] . Naturally, the optimal PAD for the elderly should not have a negative effect on the work of the heart and other internal organs, on the cognitive and other functions of the brain, and interact with other drugs. According to the recommendations of the International Antiepileptic League (based on data from randomized clinical trials), gabapentin and lamotrigine are the drugs of choice for the therapy of newly diagnosed epilepsy in the elderly. Unfortunately, up to 30% of patients with epilepsy are resistant to PAD [6] .
Autonomous nerve system and seizures.
Resistance can be observed from the onset of the disease or form during the course of the illness [13] . When establishing resistance, the question arises of choosing nondrug therapies: vagal stimulation or surgical intervention on the brain. Stimulation of the vagus nerve consists of subcutaneous implanta tion of the device that generates pulses and the con nection of the electrodes to the left vagus nerve [1, 8, 12] . The mechanism of action of vagus nerve stimulation is not completely clear, presumably, it is associated with activation of the reticular formation of the brain stem. Günümüzdə epilepsiyanın inkişafının həqiqi səbəbini təyin etmək kifayət qədər çətindir. Bu xüsusilə epilepsiyanın hər hansı bilinməyən səbəbdən yaranan idiopatik və kriptogen formalarına münasibətdə özünü doğruldur. Belə vəziyyətlərdə beyində və ya digər orqanlarda bu patologiyanın inkişafına səbəb olan dəyişikliklər olmur. Əgər epilepsiyanın idiopatik forması varsa, pasiyent əlillik qrupu almalıdır. Bu onunla əlaqədardır ki, bu xəstəlik insanın
